INT477

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.81
First Reported 1975
Last Reported 2010
Negated 9
Speculated 9
Reported most in Abstract
Documents 813
Total Number 823
Disease Relevance 131.58
Pain Relevance 300.40

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Avp) extracellular space (Avp) extracellular region (Avp)
response to stress (Avp) signal transducer activity (Avp)
Anatomy Link Frequency
neurohypophysis 42
nucleus 35
plasma 27
hypothalamus 24
pituitary 24
Avp (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 1045 100.00 Very High Very High Very High
narcan 1040 100.00 Very High Very High Very High
agonist 655 100.00 Very High Very High Very High
Opioid 468 100.00 Very High Very High Very High
Enkephalin 448 100.00 Very High Very High Very High
noradrenaline 236 100.00 Very High Very High Very High
Neuropeptide 213 100.00 Very High Very High Very High
substance P 192 100.00 Very High Very High Very High
Dynorphin 174 100.00 Very High Very High Very High
Dopamine 167 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Urological Neuroanatomy 90 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 53 100.00 Very High Very High Very High
Fever 46 100.00 Very High Very High Very High
Hyperplasia 32 100.00 Very High Very High Very High
Cv General 3 Under Development 20 99.98 Very High Very High Very High
Anxiety Disorder 165 99.96 Very High Very High Very High
Hypertension 90 99.96 Very High Very High Very High
Hyponatremia 515 99.92 Very High Very High Very High
Pressure Volume 2 Under Development 264 99.92 Very High Very High Very High
Pressure And Volume Under Development 204 99.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, the expected corresponding increase in urinary excretion of vasopressin (AVP) did not occur.
Localization (excretion) of vasopressin
1) Confidence 0.81 Published 1988 Journal Endocrinol. Exp. Section Abstract Doc Link 3265380 Disease Relevance 0.98 Pain Relevance 0
However, the expected corresponding increase in urinary excretion of vasopressin (AVP) did not occur.
Localization (excretion) of AVP
2) Confidence 0.81 Published 1988 Journal Endocrinol. Exp. Section Abstract Doc Link 3265380 Disease Relevance 0.98 Pain Relevance 0
Arginine vasopressin (AVP) has been localized in numerous extrahypothalamic brain regions and in the spinal cord.
Localization (localized) of AVP in spinal cord associated with spinal cord
3) Confidence 0.81 Published 1985 Journal Regul. Pept. Section Abstract Doc Link 3839086 Disease Relevance 0 Pain Relevance 0.16
Arginine vasopressin (AVP) has been localized in numerous extrahypothalamic brain regions and in the spinal cord.
Localization (localized) of Arginine vasopressin in spinal cord associated with spinal cord
4) Confidence 0.81 Published 1985 Journal Regul. Pept. Section Abstract Doc Link 3839086 Disease Relevance 0 Pain Relevance 0.16
Intravenous injection of naloxone significantly increased the basal AVP level and carbachol-induced AVP secretion.
Localization (secretion) of AVP associated with narcan
5) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Abstract Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.65
To clarify the role of endogenous opioid peptides in the control of vasopressin (AVP) secretion, the effects of an endogenous kappa-agonist, leumorphin, derived from proenkephalin B and an opioid antagonist, naloxone, on AVP secretion were examined in conscious and freely moving rats.
Localization (secretion) of vasopressin associated with antagonist, narcan, agonist, endogenous opioid and opioid
6) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Abstract Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.62
Intraperitoneal injection of nicotine markedly increased AVP secretion in rats.
Localization (secretion) of AVP associated with nicotine
7) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Abstract Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.66
To clarify the role of endogenous opioid peptides in the control of vasopressin (AVP) secretion, the effects of an endogenous kappa-agonist, leumorphin, derived from proenkephalin B and an opioid antagonist, naloxone, on AVP secretion were examined in conscious and freely moving rats.
Localization (secretion) of AVP associated with antagonist, narcan, agonist, endogenous opioid and opioid
8) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Abstract Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.66
Opioid modulation of vasopressin secretion in conscious rats.
Localization (secretion) of vasopressin associated with opioid
9) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Title Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.82
To clarify the role of endogenous opioid peptides in the control of vasopressin (AVP) secretion, the effects of an endogenous kappa-agonist, leumorphin, derived from proenkephalin B and an opioid antagonist, naloxone, on AVP secretion were examined in conscious and freely moving rats.
Localization (secretion) of AVP associated with antagonist, narcan, agonist, endogenous opioid and opioid
10) Confidence 0.81 Published 1988 Journal Clin Exp Hypertens A Section Abstract Doc Link 3243002 Disease Relevance 0 Pain Relevance 0.62
The functional role of the nucleus tractus solitarius (NTS) in the regulation of arginine-vasopressin (AVP) release mediated by baroreceptor activation was investigated by examining the effects induced by the presynaptic alpha-adrenergic agonist clonidine.
Localization (release) of arginine-vasopressin in nucleus associated with agonist and clonidine
11) Confidence 0.81 Published 1990 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 1982697 Disease Relevance 0.08 Pain Relevance 0.30
Alpha 2-adrenergic stimulation within the nucleus tractus solitarius attenuates vasopressin release induced by depletion of cardiovascular volume.
Localization (release) of vasopressin in nucleus
12) Confidence 0.81 Published 1990 Journal Pharmacol. Biochem. Behav. Section Title Doc Link 1982697 Disease Relevance 0.08 Pain Relevance 0.30
These findings suggest that catecholaminergic projections from NTS to hypothalamic vasopressinergic neurons play a facilitatory role in controlling AVP secretion.
Localization (secretion) of AVP in neurons
13) Confidence 0.81 Published 1990 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 1982697 Disease Relevance 0.08 Pain Relevance 0.28
The functional role of the nucleus tractus solitarius (NTS) in the regulation of arginine-vasopressin (AVP) release mediated by baroreceptor activation was investigated by examining the effects induced by the presynaptic alpha-adrenergic agonist clonidine.
Localization (release) of AVP in nucleus associated with agonist and clonidine
14) Confidence 0.81 Published 1990 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 1982697 Disease Relevance 0.08 Pain Relevance 0.30
The present data show that microinjection of clonidine into NTS resulted in a significant attenuation of AVP secretion induced by hypovolemia in the rat.
Localization (secretion) of AVP associated with pressure volume 2 under development and clonidine
15) Confidence 0.81 Published 1990 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 1982697 Disease Relevance 0.10 Pain Relevance 0.34
To elucidate the role of leumorphin, a kappa-agonist derived from proenkephalin-B (neoendorphin/dynorphin precursor), in the control of arginine vasopressin (AVP) secretion, we examined the effects of intracerebroventricular (icv) administration of leumorphin on AVP secretion under basal and stimulated conditions in conscious unrestrained rats.
Localization (secretion) of AVP associated with dynorphin, agonist and intracerebroventricular
16) Confidence 0.81 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.22
Intracerebroventricular administration of leumorphin (600 pmol) also reduced the AVP secretion stimulated by icv injection of carbachol (50 pmol).
Localization (secretion) of AVP associated with intracerebroventricular
17) Confidence 0.81 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.24
However, no effect on AVP secretion was observed after iv injection of leumorphin (600 pmol).
Localization (secretion) of AVP
18) Confidence 0.81 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.22
Intravenous pretreatment with naloxone (0.5 mg/kg BW) diminished the inhibitory action of leumorphin (60 pmol) on AVP secretion.
Localization (secretion) of AVP associated with narcan
19) Confidence 0.81 Published 1988 Journal Endocrinology Section Abstract Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.23
Inhibitory action of leumorphin on vasopressin secretion in conscious rats.
Localization (secretion) of vasopressin associated with enkephalin
20) Confidence 0.81 Published 1988 Journal Endocrinology Section Title Doc Link 3342763 Disease Relevance 0 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox